Association Between Hepatitis C Infection and Renal Cell Carcinoma


The purpose of this study is to determine if there is an association between hepatitis C infection and kidney cancer. All patients who are diagnosed with kidney cancer and who will either have a biopsy or surgery will be offered to be tested for hepatitis C. The control group will be colon cancer patients. Both groups would be of recent diagnosis (6 months).

Full Title of Study: “Association Between Hepatitis C Infection and Renal Cell Carcinoma, a Case Control Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2013


  • Other: Hepatitis C testing
    • Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype

Arms, Groups and Cohorts

  • Renal Cell Carcinoma patients
    • Newly diagnosed (within 6 months) renal cell carcinoma patients in who a biopsy or surgery will be performed
  • Colorectal cancer patients
    • Newly diagnosed (6 months) colon cancer patients

Clinical Trial Outcome Measures

Primary Measures

  • Prevalence of hepatitis C in renal cell carcinoma patients
    • Time Frame: 2 years
    • Determine the prevalence of hepatitis C infection in newly diagnosed renal cell carcinoma patients

Participating in This Clinical Trial

Inclusion Criteria

  • Male and female patients 18 years or older in whom renal cell carcinoma is suspected and are scheduled for either biopsy or partial or total nephrectomy. Diagnosis within 6 months.
  • Male and female patients 18 years or older in whom colorectal cancer has been diagnosed within the last 6 months

Exclusion Criteria

  • Patients who are unwilling to provide consent
  • Patients who decline to complete a questionnaire
  • Patient in who blood sample cannot be obtained
  • Diagnosis of renal cell carcinoma or colon cancer greater than 6 months

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Henry Ford Health System
  • Collaborator
    • Schering-Plough
  • Provider of Information About this Clinical Study
    • Principal Investigator: Humberto C. Gonzalez, MD – Henry Ford Health System
  • Overall Official(s)
    • Humberto C Gonzalez, MD, Principal Investigator, Henry Ford Hospital
    • Stuart C Gordon, MD, Study Chair, Henry Ford Hospital


Gordon SC, Moonka D, Brown KA, Rogers C, Huang MA, Bhatt N, Lamerato L. Risk for renal cell carcinoma in chronic hepatitis C infection. Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1066-73. doi: 10.1158/1055-9965.EPI-09-1275. Epub 2010 Mar 23.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.